SCHEMBL4080930

SCHEMBL4080930

CCOC(=O)c1c(NC(=O)C2C(C)(C)C2(C)C)sc2c1CCOC2

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 4/20 0.69
KMT2A Q03164 1/20 0.59
ALDH1A1 P00352 8/20 0.57
MAPT P10636 5/20 0.57
LMNA P02545 4/20 0.57
TSHR P16473 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
KDM4E B2RXH2 4/20 0.51
HTT P42858 2/20 0.51
CNR1 P21554 1/20 0.51
ALOX15 P16050 1/20 0.50
MAPK1 P28482 1/20 0.50
HSD17B10 Q99714 1/20 0.50
NPSR1 Q6W5P4 2/20 0.49
HPGD P15428 1/20 0.49
RPS6KB1 P23443 1/20 0.49
CDK2 P24941 1/20 0.49
MAPKAPK2 P49137 1/20 0.49
GSK3B P49841 1/20 0.49
RPS6KA3 P51812 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5450569 0.88 KMT2A (0.69) CNR2KMT2AALDH1A1MAPTLMNA
SCHEMBL4090835 0.87 KMT2A (0.55) CNR2KMT2AALDH1A1MAPTLMNA
SCHEMBL5460524 0.86 ALDH1A1 (0.56) CNR2KMT2AALDH1A1MAPTLMNA
SCHEMBL5453100 0.86 CNR2 (0.67) CNR2KMT2AALDH1A1MAPTLMNA
SCHEMBL5460031 0.86 MAPT (0.56) CNR2KMT2AALDH1A1MAPTLMNA
SCHEMBL5460238 0.86 CNR2 (0.64) CNR2KMT2AALDH1A1MAPTLMNA
SCHEMBL4084162 0.85 MAPT (0.72) CNR2KMT2AALDH1A1MAPTLMNA
SCHEMBL4084306 0.85 CNR1 (0.69) CNR2ALDH1A1MAPTLMNATSHR
SCHEMBL5450611 0.85 CNR2 (0.66) CNR2KMT2AALDH1A1MAPTLMNA
SCHEMBL4094543 0.85 CNR2 (0.66) CNR2KMT2AALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338623-B2 N-{3-[(2,5-dimethylmorpholin-4-yl)carbonyl]-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl}hexahydro-2,5-methanopentalene-3a(1H)-carboxamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants ABBVIE INC. (US) 2012-12-25 US disclosed
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2009-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, GPR18 CNR2 2/4885KMT2A 2505/4885ALDH1A1 1504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.